Currently, there are 208.62M common shares owned by the public and among those 199.07M shares have been available to trade.
The company’s stock has a 5-day price change of -9.30% and 131.10% over the past three months. SGMO shares are trading 258.92% year to date (YTD), with the 12-month market performance up to 302.06% higher. It has a 12-month low price of $0.30 and touched a high of $3.18 over the same period. SGMO has an average intraday trading volume of 7.30 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.19%, 14.63%, and 109.59% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Sangamo Therapeutics Inc (NASDAQ: SGMO) shares accounts for 27.00% of the company’s 208.62M shares outstanding.
It has a market capitalization of $406.86M and a beta (3y monthly) value of 1.18. The earnings-per-share (ttm) stands at -$0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.72% over the week and 12.86% over the month.
Earnings per share for the fiscal year are expected to increase by 66.55%, and 68.18% over the next financial year.
Looking at the support for the SGMO, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on Dec-11-24, with the firm’s price target at $10. RBC Capital Mkts coverage for the Sangamo Therapeutics Inc (SGMO) stock in a research note released on November 03, 2023 offered a Sector Perform rating with a price target of $2. BofA Securities was of a view on April 28, 2023 that the stock is Underperform, while Wedbush gave the stock Outperform rating on February 27, 2023, issuing a price target of $16. BofA Securities on their part issued Neutral rating on January 06, 2023.
